Project Grant R01CA312128
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Forest Hills, TN 37215, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded Vanderbilt University Medical Center $695,884 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate selective loss of HLA gene products in triple-negative breast cancer immunobiology. The research examines how tumor cells evade immune checkpoint inhibition through downregulation or deletion of MHC-I (major histocompatibility complex I) expression. Preliminary data from the recipient's...
- The National Cancer Institute awarded Vanderbilt University $119,735 on January 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research on neutrophil-driven pro-recurrent niche formation in mammary adipose tissue following radiation therapy for triple negative breast cancer. The research tests the hypothesis that neutrophils facilitate formation of a pro-recurrent niche in irradiated mammary adipose tissue through release of pro-inflammatory proteins and...
- The National Cancer Institute awarded the University of Tennessee Health Science Center $389,215 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop selective N-glycan biosynthesis inhibitors targeting metastatic triple-negative breast cancer. The research employs structure-guided medicinal chemistry to optimize DPAGT1 (dolichyl-phosphate N-acetylglucosaminephosphotransferase 1) inhibitors, the first committed enzyme in N-glycan biosynthesis. The project...
- The National Cancer Institute awarded $400,000 to Toomer Therapeutics, Inc. on September 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small-molecule inhibitors of the E3 ubiquitin ligase ARIH1 as a targeted therapy for triple-negative breast cancer and other cancers. The project focuses on lead compound optimization, absorption-distribution-metabolism-excretion and pharmacokinetic studies to generate drug-like ARIH1 inhibitors, and preclinical efficacy studies of...
- The National Cancer Institute awarded the University of Kansas Medical Center Research Institute, Inc. $398,544 on April 8, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct pre-clinical evaluation of a highly selective SMARCA2 degrader in therapy-resistant triple-negative breast cancer. The research addresses mechanisms of resistance to neoadjuvant systemic therapy in triple-negative breast cancer patients with residual disease. The project leverages the recipient's...
- The National Cancer Institute awarded $668,878 to the University of Texas at Austin on April 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates targeting CD44 variant 9 for advanced and treatment-resistant breast cancer. The research addresses the clinical need for new therapeutic options for patients with triple-negative and heavily treated hormone receptor-positive metastatic breast cancer who have relapsed or progressed after current...
- The National Cancer Institute awarded Texas A&M University System Health Science Center a $327,250 cooperative agreement on July 3, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify natural products targeting castration-resistant prostate cancer driven by androgen receptor splice variants, particularly AR-V7. During the UG3 phase, the recipient will miniaturize and transfer optimized phenotypic assays into a 1536-well format, establish robust cell-line...
- The National Cancer Institute awarded Vanderbilt University $101,838 on December 26, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical training in cancer research. The award funds development of novel anti-EGFR peptides as therapeutic candidates for non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinomas, and glioblastomas. The project integrates protein modeling and peptide design methods with experimental screening to generate...
- The National Cancer Institute awarded Vanderbilt University $709,630 under the Cancer Treatment Research program (CFDA 93.395) on July 1, 2026, to develop and evaluate a novel combination therapy for BCG-refractory and BCG-recurrent non-muscle-invasive bladder cancer. The research combines intravesical delivery of oncolytic reovirus and immune checkpoint inhibitors with targeted internal radiation therapy using the sodium/iodide symporter to render bladder cancer cells susceptible to radioactive...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Natsar Pharmaceuticals, Inc. a $1.63 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) on September 22, 2025, for the development of RK-33, a small molecule inhibitor targeting DDX3 (DEAD-box helicase 3) as a therapeutic candidate for triple-negative breast cancer (TNBC). The grant supports drug development activities through August 31, 2027, advancing a rationally designed compound that has...